WO2017087947A3 - Method of treatment of follicular lymphoma with a btk inhibitor - Google Patents

Method of treatment of follicular lymphoma with a btk inhibitor Download PDF

Info

Publication number
WO2017087947A3
WO2017087947A3 PCT/US2016/063085 US2016063085W WO2017087947A3 WO 2017087947 A3 WO2017087947 A3 WO 2017087947A3 US 2016063085 W US2016063085 W US 2016063085W WO 2017087947 A3 WO2017087947 A3 WO 2017087947A3
Authority
WO
WIPO (PCT)
Prior art keywords
individual
follicular lymphoma
treatment
p2ry11
btk inhibitor
Prior art date
Application number
PCT/US2016/063085
Other languages
French (fr)
Other versions
WO2017087947A2 (en
Inventor
Zhengyuang WANG
Betty Chang
Leo Cheung
Karl Eckert
Karl SCHWEIGHOFER
Shiquan Wu
Original Assignee
Pharmacyclics Llc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Pharmacyclics Llc filed Critical Pharmacyclics Llc
Publication of WO2017087947A2 publication Critical patent/WO2017087947A2/en
Publication of WO2017087947A3 publication Critical patent/WO2017087947A3/en

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
    • C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
    • C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
    • C12Q1/6886—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material for cancer
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/106—Pharmacogenomics, i.e. genetic variability in individual responses to drugs and drug metabolism
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q2600/00—Oligonucleotides characterized by their use
    • C12Q2600/158—Expression markers

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • General Health & Medical Sciences (AREA)
  • Pathology (AREA)
  • Analytical Chemistry (AREA)
  • Zoology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Wood Science & Technology (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • General Chemical & Material Sciences (AREA)
  • Oncology (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Molecular Biology (AREA)
  • Hospice & Palliative Care (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)

Abstract

Disclosed herein are methods of treating follicular lymphoma in an individual in need thereof wherein the individual has an overexpression of one or more genes selected from CALB2, P2RY11 (PPAN-P2RY11), DNAJC8, TTC19, VCAMl, CSAG3, GP1BA, RPA1, RSC1A1, STS-1 (UBASH3B), ADPRM (C170RF48) and FILIPl, or a normal expression or underexpression of one or more genes selected from CERCAM, POM121C (LOC100131972), PPP1R3D, PLOD2, SDHA (SDHAP3), OSBPL2, HCFC1R1, and DHRS7, which method comprises administering or continuing to administer to the individual a therapeutically effective amount of ibrutinib or a pharmaceutically acceptable salt or solvate thereof.
PCT/US2016/063085 2015-11-19 2016-11-21 Method of treatment of follicular lymphoma with a btk inhibitor WO2017087947A2 (en)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US201562257563P 2015-11-19 2015-11-19
US62/257,563 2015-11-19
US201662280562P 2016-01-19 2016-01-19
US62/280,562 2016-01-19

Publications (2)

Publication Number Publication Date
WO2017087947A2 WO2017087947A2 (en) 2017-05-26
WO2017087947A3 true WO2017087947A3 (en) 2017-07-06

Family

ID=58717880

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2016/063085 WO2017087947A2 (en) 2015-11-19 2016-11-21 Method of treatment of follicular lymphoma with a btk inhibitor

Country Status (1)

Country Link
WO (1) WO2017087947A2 (en)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
MX2020004501A (en) 2010-06-03 2021-11-09 Pharmacyclics Llc The use of inhibitors of bruton's tyrosine kinase (btk).
KR20180088926A (en) 2012-07-24 2018-08-07 파마싸이클릭스 엘엘씨 Mutations associated with resistance to inhibitors of bruton's tyrosine kinase (btk)
AU2019388899A1 (en) * 2018-11-30 2021-06-10 Janssen Biotech, Inc. Methods of treating follicular lymphoma
CN111481666B (en) * 2019-01-28 2024-05-24 中国科学院大连化学物理研究所 Application of inhibitor capable of inhibiting CALB2 protein expression and liver cancer medicine
WO2023105119A1 (en) * 2021-12-07 2023-06-15 Sartar Therapeutics Oy Synergistic compositions for use in the treatment of cancer

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059854A1 (en) * 2001-09-05 2011-03-10 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
WO2014168975A1 (en) * 2013-04-08 2014-10-16 Pharmacyclics, Inc. Ibrutinib combination therapy

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20110059854A1 (en) * 2001-09-05 2011-03-10 The Brigham And Women's Hospital, Inc. Diagnostic and prognostic tests
WO2014168975A1 (en) * 2013-04-08 2014-10-16 Pharmacyclics, Inc. Ibrutinib combination therapy

Also Published As

Publication number Publication date
WO2017087947A2 (en) 2017-05-26

Similar Documents

Publication Publication Date Title
WO2017087947A3 (en) Method of treatment of follicular lymphoma with a btk inhibitor
AU2018372763A1 (en) Materials and methods for treatment of autosomal dominant Retinitis Pigmentosa
WO2018154462A3 (en) Materials and methods for treatment of spinocerebellar ataxia type 2 (sca2) and other spinocerebellar ataxia type 2 protein (atxn2) gene related conditions or disorders
WO2018140920A8 (en) Compositions and methods for inhibition of factor xii gene expression
WO2016106404A3 (en) Methods and compositions for treating malignant tumors associated with kras mutation
WO2012174338A3 (en) Method of selecting therapeutic indications
WO2019226514A3 (en) Molecular gene signatures and methods of using same
EP4253412A3 (en) Inhibition of cytokine-induced sh2 protein in nk cells
FI3618875T3 (en) Combination therapy comprising a raf inhibitor and trametinib
WO2015106128A3 (en) Rnai agents modified at the 4'-c-position
MX354940B (en) Functionally-modified oligonucleotides and subunits thereof.
MX2011012311A (en) Genetic markers associated with interferon-alpha response.
WO2017106364A3 (en) Compositions and methods for treatment of retinitis pigmentosa 18 and retinitis pigmentosa 13
MX2020011415A (en) Methods of using zscan4 for rejuvenating human cells.
EP4286013A3 (en) Lrrc33 inhibitors and use thereof
WO2017069288A8 (en) Pharmaceutical composition for use in treating aml and method of treating aml in a subject in need thereof
MX2021013913A (en) Compositions and methods for the treatment of atpase-mediated diseases.
AU2016206832A8 (en) Non-invasive systems and methods for treatment of a host carrying a virus with photoactivatable drugs
WO2017035176A8 (en) Method of preventing or treating obesity with an emc10 inhibitor
EP3590338A3 (en) Medical treatments based on anamorelin
WO2017011356A3 (en) Mcj inhibitors for use in treating drug-induced diseases and conditions
BR112018010736A2 (en) antisense oligonucleotides against il-34 and methods of using them
TW201613639A (en) Methods for treating cardiovascular diseases
MX2021006915A (en) Cxcr7 inhibitors for the treatment of cancer.
WO2019079618A3 (en) Formulations for treatment of skin conditions

Legal Events

Date Code Title Description
121 Ep: the epo has been informed by wipo that ep was designated in this application

Ref document number: 16867329

Country of ref document: EP

Kind code of ref document: A2

NENP Non-entry into the national phase

Ref country code: DE

122 Ep: pct application non-entry in european phase

Ref document number: 16867329

Country of ref document: EP

Kind code of ref document: A2